logo
Plus   Neg
Share
Email

Amgen's Phase 3 CANDOR Study Meets Primary Endpoint Of PFS - Quick Facts

Amgen (AMGN) said Friday that the Phase 3 CANDOR study evaluating KYPROLIS in combination with dexamethasone and DARZALEX or KdD compared to KYPROLIS and dexamethasone alone met its primary endpoint of progression-free survival.

The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma treated with KdD.

The CANDOR data will be submitted to a future medical meeting and discussed with health authorities in preparation for regulatory submissions, the company said in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The University of Phoenix has agreed to pay a record $191 million to settle Federal Trade Commission charges alleging that the university used deceptive advertisements. According to the FTC, the university used deceptive advertisements that falsely touted their relationships and job opportunities... General Motors introduced new versions of its Chevrolet Tahoe and Suburban full-size SUVs that are bigger than previous models, offer more interior space and feature more advanced technology. The new vehicles join the new Silverado and Silverado HD as part of a complete redesign of Chevrolet's full-size truck and SUV lineup within 24 months. They will go on sale in mid-2020 in North America. Apple unveiled a new feature for the Apple Card, enabling cardholders to buy a new iPhone in 24 monthly installments without paying interest. In October, during Apple's earnings call, CEO Tim Cook had announced the tech giant's plans to introduce this feature. The Apple Card, Apple's first credit card, was introduced by the tech giant in March in partnership with Goldman Sachs and Mastercard.
Follow RTT
>